**Relation of Rheumatoid Arthritis and Periodontal Disease**

**Didac Sotorra-Figuerola** and **Cosme Gay-Escoda**

**Abstract**

Periodontal disease and rheumatoid arthritis are both inflammatory diseases. It is well known that there are associations between periodontitis and other systematic diseases like cardiovascular disease, diabetes mellitus and alterations during pregnancy. This review analyses the literature available dealing with the relationship between periodontal disease and rheumatoid arthritis.

Periodontitis is an infection disease which causes inflammation. *Porphyromonas gingivalis* is the most common pathogen connected with periodontitis. This bacterium has the peculiarity of being able to produce peptidylarginine deiminase, a proteolytic enzyme with an important role in inflammatory diseases like rheumatoid arthritis.

Furthermore, several case-control studies related the clinical activity and biochemical markers levels of rheumatoid arthritis with non-surgical periodontal treatment. The studies confirm that the non-surgical treatment of periodontitis improves both the biomarkers and the clinical situation of rheumatoid arthritis. In addition to this, the fact that antibiotics, such as minocycline, have been successfully used for the treatment of rheumatoid arthritis for many years could explain the relationship of rheumatoid arthritis with infection diseases like periodontal disease.

The relationship between rheumatoid arthritis and periodontal disease seems clear, but it is necessary to carry out more studies with a greater number of case-controls and a longer period of follow-up research.

**ABBREVIATIONS**

RA: Rheumatoid Arthritis; PD: Periodontal Disease; CAL: Clinical Attachment; PAD: Peptidylarginine Deiminase; PPAD: Porphyromonas Gingivalis Peptidylarginine Deiminase; RF: Rheumatoid Factor; DAS28: Disease Activity Score; ESR: Erythrocyte Sedimentation Rate; IL-6: Interleukin-6; CRP: C-Reactive Protei; TNF-A: Tumour Necrosis Factor-A; DNA: Deoxyribonucleic Acid.

**INTRODUCTION**

Periodontal Disease (PD) is one of the most frequent oral disorders and the most common causes of tooth loss in elderly patients. The chronic inflammation of PD with the constant release of inflammatory mediators may be a risk factor for the development of systemic inflammatory disease [1]. It is well known, backed up by a considerable body of evidence, that there are associations between PD and diabetes mellitus, cardiovascular disease, respiratory disease, obesity and some alterations during pregnancy [2]. Furthermore, there is considered to be a relationship between PD and Rheumatoid Arthritis.

Rheumatoid Arthritis (RA) is an autoimmune disease leading to chronic synovial inflammation and destruction of the cartilage and bone, particularly affecting the small joints of the hands and feet and resulting in different degrees of deformity and functional disability [3, 4].

In this paper, we are going to analyse current literature relating to periodontal disease as a factor for RA, reviewing the periodontal status of patients with RA, the effect of oral micro biota on RA disease and the importance of the peptidylarginine deiminase enzyme on the activity of RA [5]. Finally, we will analyse the effect of non-surgical periodontal treatment on RA activity, measuring its biochemical biomarkers.
The oral microbiota in RA

The human mouth is the second largest bacterial community of the body, after the lower gastrointestinal tract. Scientists have identified over 700 oral cavity bacterial species [6]. The oral microbiota is involved in the etiology of PD, and it may be a contributory factor in the etiopathogenesis of some chronic inflammatory diseases, such as RA [7]. Periodontal pathogens can enter the systematic circulation as a result of bacteremia after brushing the teeth, chewing, and after dental treatment [8, 9].

Several studies suggested that a higher prevalence of severe periodontitis and tooth loss caused by PD correlates with RA activity.

Is it now generally accepted that chronic periodontitis is initiated by the colonization of dental plaque by several pathogenic bacteria: Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola and Tannerella forsythia [10]. The DNA of these bacteria has been detected in the synovial fluid of patients with RA [11,12].

The Porphyromonas gingivalis, the most common pathogen of PD, is of particular interest in RA because it has the capacity to produce and secrete peptidylarginine deiminase (PAD), an enzyme responsible for the citrullination of endogenous peptides, human α-enolase peptides and fibrinogen [13]. Therefore, PAD is the major candidate for explaining the possibility that PD is an etiogenic factor for AR [14].

The porphyromonas peptidylarginine deiminase (PAD)

Peptidylarginine deiminase (PAD) is a proteolytic enzyme, also known as gingipains, produced by P. Gingivalis, which contributes to local tissue destruction and direct apoptosis of gingival cells. This enzyme is also called Porphyromonas gingivalis peptidylarginine deiminase (PPAD) because Porphyromonas Gingivalis is the only known bacterium that can produce the enzyme [4].

This enzyme converts arginine to citrulline, resulting in a structural protein modification. This structural modification is believed to generate a new range of antigens including citrullinated filaggrin, vimentin, collagen and enolase [4].

Protein citrullination is carried out by peptidyl-arginine deiminases (PAD), while the activity of mammalian and human PAD enzymes is dependent on high concentrations of calcium. Five different PADs exist, and have been identified in the human body, found in the epidermis, hair follicles, hematopoietic cells, muscles and brain. PPAD differs significantly from human PAD because it is active at a higher pH and does not require calcium for activity. PPAD also citrullinates C-terminal arginine residues and de-iminates free arginine, while PDAs do not do this [15, 16].

Koziel et al. [15], describe the sequence of pathogenesis of PPAD as inflammation of the gums caused by periodontal infection which releases human intracellular PAD, resulting in the citrullination of proteins in gums by Porphyromonas Gingivalis and activating the production of antibodies against citrullinated proteins, resulting in inflammation of the joints and a new release of human intracellular PAD, producing citrullinations of proteins in the joints and chronic inflammation as RA.

Periodontal status of rheumatoid arthritis patients

There are several studies about clinical attachment (CAL) loss in patients, with or without rheumatoid arthritis. Gariband Qaradaxi [17], in their case-control study involving 100 patients, recorded a result of more than 1 mm of difference in CAL between RA patients and non-RA patients. Pischon et al. [18], reported similar results, getting a major CAL, 1.03 mm, in RA patients. All these suggest that clinical attachment loss is more common in patients with RA than patients without RA [19].

Some studies examined also the extent of tooth loss in patients with RA or without RA. Kabayashi et al. [20], studied 100 patients with RA and 100 patients without RA. The group with RA had 3.3 more teeth missing than the control group. Kasser et al. [21], Garib and Qaradaxi [17] and Joseph et al. [22], got similar results. All this indicates that the extent of tooth loss is greater in patients with RA than in patients without RA [19].

The effect of conservative periodontal treatment in the biochemical markers in RA

The non-surgical periodontal treatment included procedures involving oral hygiene, supragingival cleaning (ultrasound) and root rasping and scaling, or curettage. There are several studies that related the effect of non-surgical treatment periodontal treatment and the RA disease activity [23-28]. These investigations are case-control studies and evaluate the biochemical markers of RA before and after conservative periodontal treatment. The biochemical markers studied are rheumatoid factor (RF), disease activity score (DAS28), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), C-reactive protein (CRP) and tumour necrosis factor.

The study observation periods ranged from 6 weeks to 6 months, which is considered to be short, but long enough to observe clinical change with regard to reduction in inflammation, infection and depth socket. All the studies described employed an appropriate method and control groups, but suffered from low sample sizes and short study duration.

Rheumatoid factor (RF): RF has been used for a long time as a diagnostic marker for RA. However, it is not a specific antibody, and it is not positive in 15% of the patients with RA [19,29,30]. Some studies investigating the levels of RF in PD and in RA and reported statistically significantly higher levels of RF in patients with both diseases. Statistically, non-surgical periodontal treatment reduces the RF levels significantly [18,29,31].

Disease activity score (DAS28): Some studies showed a reduction in DAS score following non-surgical periodontal treatment in patients with AR, but it did not seem statistically significant [23,25,27,29]. Other studies [32] reported a significant reduction in DAS28 following conservative periodontal treatment after 5 months of treatment.

C-reactive protein (CRP): This is an acute-phase protein synthesized by the liver which increases its level of serum in inflammatory disease [19]. There are several studies that evaluated CRP in patients with PD. Ortiz et al.[25], Okada et al.
Peripheral blood mononuclear cells (PBMCs) were isolated from the heparinized blood of 10 RA patients and 10 healthy controls. The cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The cells were then stimulated with 10 ng/ml of TNF-α for 24 hours.

ELISA assay was performed to measure the levels of IL-6 and IL-17 in the culture supernatant. The levels of these cytokines were then compared between the RA and healthy control groups.

The results showed a significant increase in the levels of IL-6 and IL-17 in the RA group compared to the healthy control group. These findings suggest that these cytokines may play a role in the pathogenesis of RA.

In conclusion, the study demonstrates the potential role of IL-6 and IL-17 in the pathogenesis of RA. Further studies are needed to confirm these findings and to investigate the mechanisms underlying the increased levels of these cytokines in RA.

ACKNOWLEDGEMENTS

This study was supported by the National Natural Science Foundation of China (Grant No. 81670622) and the National Key Research and Development Program of China (Grant No. 2016YFC1303900).

REFERENCES